Warfarin
- Generic Name
- Warfarin
- Brand Names
- Coumadin, Jantoven
- Drug Type
- Small Molecule
- Chemical Formula
- C19H16O4
- CAS Number
- 81-81-2
- Unique Ingredient Identifier
- 5Q7ZVV76EI
- Background
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ...
- Indication
Indicated for:
1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.
2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.
3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.
...
- Associated Conditions
- Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
- Associated Therapies
- -
Safety and Effectiveness of Early Aspirin Administration After Mitral Valve Repair
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 384
- Registration Number
- NCT06738992
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Target Recruit Count
- 57
- Registration Number
- NCT06723691
- Locations
- 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates
- Conditions
- Interventions
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 20
- Registration Number
- NCT06686628
- Locations
- 🇩🇪
Investigational Site Number : 2760001, Berlin, Germany
Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients with Assist Device
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 128
- Registration Number
- NCT06655376
- Locations
- 🇺🇸
Columbia Irving Medical Center, New York, New York, United States
The Safety and Effectiveness of Warfarin Vs Apixaban in Patients with NVAF/ VTE and ESKD on Dialysis
- Conditions
- Interventions
- First Posted Date
- 2024-09-20
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Abu Dhabi Health Services Company
- Target Recruit Count
- 67
- Registration Number
- NCT06606275
- Locations
- 🇦🇪
SEHA Tawam Hospital, Al Ain, Abu Dhabi, United Arab Emirates
Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 212
- Registration Number
- NCT06515730
A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin
- Conditions
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT06335134
- Locations
- 🇨🇳
West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight
- Conditions
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 30
- Registration Number
- NCT06289504
- Locations
- 🇨🇦
Altasciences Company Inc., Mount-Royal, Quebec, Canada
An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism
- Conditions
- Interventions
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 320
- Registration Number
- NCT06278051
- Locations
- 🇯🇵
Many facilities, Multiple Locations, Japan
🇯🇵Bayer, Osaka, Japan
Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin As Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE
- Conditions
- Interventions
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT05995600
- Locations
- 🇰🇷
Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of
🇰🇷Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷Yeungnam University Medical Center, Daegu, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.